FUS-ALS and Ulefnersen: What a Japanese Specialist Second Opinion Should Review

Published: 2026-09-23 · Sources checked: 2026-09-23 · Medical review: pending professional review.

Direct answer: On 22 September 2026, Otsuka Pharmaceutical reported that investigational ulefnersen (ION363) met the primary endpoint in the main analysis of the global FUSION study for ALS caused by pathogenic FUS variants. This is an important Phase 3 result, but ulefnersen is not approved in Japan, the United States, or elsewhere, and the finding does not apply to every person with ALS.

For a patient with young-onset or rapidly progressive motor neuron disease, or a report identifying a FUS variant, the immediate question is not how to obtain the drug. The first questions are whether the ALS diagnosis is secure, whether the variant is genuinely disease-causing, and whether respiratory, swallowing, nutritional and communication needs are being addressed without delay.

Why families may still face uncertainty

ALS is biologically diverse. Otsuka estimates that FUS-related ALS represents about 0.6% of all ALS. A headline about a gene-targeted trial can therefore be misleading if it is interpreted as a treatment advance for every ALS subtype.

A laboratory report that lists a FUS variant is also not sufficient on its own. Specialists must distinguish pathogenic and likely pathogenic variants from variants of uncertain significance, then compare the genetic finding with age at onset, pattern of weakness, electromyography, family history and alternative diagnoses.

What the clinical trial actually showed

FUSION is a global multicentre, randomised, double-blind, placebo-controlled Phase 1–3 programme. In Part 1, participants received study treatment for 72 weeks. The primary analysis used a joint rank endpoint combining change in ALSFRS-R function, initiation of rescue treatment, permanent ventilation and survival-related outcomes.

According to Otsuka's top-line announcement, ulefnersen showed a statistically significant benefit over placebo on the primary endpoint (p=0.0005), with supportive findings in several secondary measures, including serum neurofilament light chain and time-to-event outcomes.

However, the full subgroup analyses, detailed adverse-event profile, durability of benefit and peer-reviewed publication are not yet available. A company announcement should not be used to stop current medication, delay respiratory support or change care without the treating team.

What a Japanese specialist may reassess

1. Whether the clinical and electrophysiological findings meet current criteria for ALS.
2. Whether cervical disease, immune-mediated neuropathy, hereditary neuropathy or another mimic has been adequately excluded.
3. The testing method, exact FUS variant and evidence supporting pathogenicity.
4. Whether genetic counselling or family testing would add useful information.
5. Disease trajectory, ALSFRS-R score, pulmonary function, swallowing, nutrition and communication needs.
6. Whether current medicines, ventilation planning, nutritional support and rehabilitation are appropriately coordinated.
7. Whether a future approval, extension study or clinical trial could realistically match the patient's molecular diagnosis and clinical condition.
8. Which recommendations can be implemented locally and whether travel to Japan would add meaningful value.

Who may reasonably consider a second opinion?

A second opinion may be useful for patients with childhood or young-adult onset, unexpectedly rapid progression, an incompletely interpreted FUS result, disagreement between medical centres, or uncertainty about eligibility for international research.

It should not be assumed that ulefnersen is relevant to a person with sporadic ALS or a different genetic subtype. Patients with worsening breathlessness, marked swallowing difficulty, repeated aspiration, rapidly increasing weakness or altered consciousness need urgent local assessment rather than waiting for an overseas written opinion.

Records commonly needed

• Neurology assessments and a dated symptom timeline
• Electromyography and nerve-conduction reports
• Brain and spinal imaging where relevant
• The complete genetic report, including variant classification and testing method
• ALSFRS-R, pulmonary function, swallowing and nutritional assessments
• Current medicines, non-invasive ventilation, feeding and rehabilitation records
• Family history and any previous genetic counselling
• Three to five questions for the reviewing specialist

Medical records and identity documents should be submitted only through a secure, access-controlled process, not in public comments.

Practical next step

Ask a neuromuscular or ALS specialist to review both the clinical diagnosis and the interpretation of the FUS variant. At the same time, make sure that respiratory, swallowing and nutritional support are not postponed while research options are explored. If a Japanese second opinion is requested, it should ideally involve expertise in motor neuron disease, neurogenetics and clinical trials.

Risks and evidence stage

Evidence stage: Phase 3 clinical trial; not an approved treatment. Meeting a primary endpoint does not guarantee regulatory approval and cannot predict an individual patient's outcome. The risks of intrathecal administration, long-term safety and durability of benefit require assessment from the complete dataset.

Frequently asked questions

Does a positive FUS result automatically make a patient eligible for ulefnersen?

No. Variant pathogenicity, the clinical diagnosis, protocol or future label criteria, and the patient's condition all require specialist review.

Is ulefnersen already available as an approved ALS medicine in Japan?

No. As of 23 September 2026, it remained investigational and had not been approved by any regulatory authority.

Should everyone with ALS undergo FUS testing?

Not automatically. Testing is particularly relevant in young-onset, familial or otherwise genetically suggestive cases. The appropriate panel and counselling plan should be chosen by neurology and genetics professionals.

Will a second opinion overturn the current plan?

Not necessarily. It may confirm the existing plan, clarify the genetic result, identify missing supportive care or describe a research pathway.

Does a Japanese opinion require travel to Japan?

No. Many diagnostic, respiratory, nutritional and rehabilitation recommendations can first be discussed with the patient's local team.

Authoritative sources

• Otsuka Pharmaceutical: top-line FUSION study results, 22 September 2026
• ClinicalTrials.gov: FUSION study, NCT04768972